生物活性 | |||
---|---|---|---|
描述 | The P2Y12 receptor, activated by ADP, plays a central role in platelet activation that have proven therapeutic value. Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of P2Y12 receptor (IC50=100nM)[3]. Clopidogrel, administered during the last three months, significantly decreases blood glucose, collagen and fibronectin expression compared to vehicle-treated diabetic mice. Clopidogrel markedly ameliorates hyperglycemia-induced renal fibrosis[4]. The combination therapy of clopidogrel and aspirin (dual-antiplatelet therapy) has been shown to be significantly beneficial compared to aspirin monotherapy and has also shown to decrease sub-acute stent thrombosis as well as recurrent ischemic events following ACS[5]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.11mL 0.62mL 0.31mL |
15.54mL 3.11mL 1.55mL |
31.07mL 6.21mL 3.11mL |
参考文献 |
---|